摘要
目的探讨P-糖蛋白(P-gp)、谷胱苷肽S转移酶(GST-π)、拓扑异构酶Ⅱ(TOPOⅡ) 在卵巢上皮性肿瘤中的表达及意义。方法应用组织微阵列技术和免疫组织化学Elivision法,检测 104例卵巢上皮性肿瘤组织中P-gp、GST-π、TOPOⅡ的耐药性表达。结果在59例卵巢癌中,P-gp、 GST-π、TOPOⅡ的耐药性表达率分别为61.02%(36/59)、49.15%(29/59)、72.88%(43/59);P-gp与 GST-π、P-gp与TOPOⅡ、GST-π与TOPOⅡ及P-gp、GST-π与TOPOⅡ的耐药共表达阳性率分别为 40.67%(24/59)、37.28%(22/59)、32.20%(19/59)、25.42%(15/59);绝经后卵巢癌GST-π的耐药表达(60.52%)高于绝经前患者(33.33%,P=0.045);分化高(G1~G2)卵巢癌TOPOⅡ的耐药表达 (80.85%)高于分化低者(G3)(50.00%,P=0.028);病情进展组P-gp耐药表达明显高于无进展组(P =0.027);P-gp、GST-π、TOPOⅡ的耐药性表达与卵巢癌组织类型、手术病理分期、腹水细胞学及有无淋巴结转移无关。结论应用免疫组织化学方法联合检测卵巢癌中P-gp、GST-π、TOPOⅡ的耐药性表达,对于临床化疗敏感性的预测有一定提示,对预后的判断可能提供有价值的参考。
Objective To detect the resistant expression of p-glycoprotein(P-gp), glutathione stransferase(GST-π), topoismarase Ⅱ (TOPO Ⅱ ) and significances in ovarian carcinoma. Methods High-throughput tissue microarray technique and Elivision immunohistochemical technique were used to investigate resistant expression of P-gp, GST-π and TOPO Ⅱ in 104 cases of ovarian carcinoma. Results In 59 cases, the expression frequency of P-gp, GST-π and TOPO Ⅱ was 61. 02% (36/59), 49. 15%(29/59) and 72. 88%(43/59), respectively. The coexpression rate of P-gp and GST-π, P-gp and TOPO Ⅱ, GST-π and TOPO Ⅱ, P-gp, GST-π and TOPO Ⅱ was 40. 67%(24/59), 37. 28% (22/59), 32. 20%(19/59), 25. 42%(15/59), respectively. The resistant expression of GST-π was higher(60. 52%) in ovarian carcinoma from patents after menopause compared with those before undergoing menopause. The expression of TOPO Ⅱ was higher(80. 85%) in ovarian carcinoma from the high-metastatic(G1-G2) than the low-metastatic(G3). Conclusion The resistant expression of P-gp, GST-π and TOPO Ⅱ were used to predict the sensitivity of chemotherapy and reference for predicting the prognosis.
出处
《贵州医药》
CAS
2006年第5期391-393,共3页
Guizhou Medical Journal